ADMA Valuation

ADMA Biologics Inc

Add to Watchlist

Advanced Chart

17.800

+0.7(4.094%)1D

Overview
Forecast
Valuation
Earnings

ADMA Relative Valuation

ADMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADMA is overvalued; if below, it's undervalued.

Historical Valuation

ADMA Biologics Inc (ADMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.25 is considered Undervalued compared with the five-year average of -0.97. The fair price of ADMA Biologics Inc (ADMA) is between 18.49 to 28.13 according to relative valuation methord. Compared to the current price of 17.07 USD , ADMA Biologics Inc is Undervalued By 7.72%.

Relative Value

Fair Zone

18.49-28.13

Current Price：17.07

7.72%

Undervalued

23.69

Trailing

Forward

14.42

EV/EBITDA

ADMA Biologics Inc. (ADMA) has a current EV/EBITDA of 14.42. The 5-year average EV/EBITDA is 9.52. The thresholds are as follows: Strongly Undervalued below -9.94, Undervalued between -9.94 and -0.21, Fairly Valued between 19.25 and -0.21, Overvalued between 19.25 and 28.98, and Strongly Overvalued above 28.98. The current Forward EV/EBITDA of 14.42 falls within the Historic Trend Line -Fairly Valued range.

17.60

EV/EBIT

ADMA Biologics Inc. (ADMA) has a current EV/EBIT of 17.60. The 5-year average EV/EBIT is 11.29. The thresholds are as follows: Strongly Undervalued below -42.41, Undervalued between -42.41 and -15.56, Fairly Valued between 38.14 and -15.56, Overvalued between 38.14 and 64.99, and Strongly Overvalued above 64.99. The current Forward EV/EBIT of 17.60 falls within the Historic Trend Line -Fairly Valued range.

7.25

ADMA Biologics Inc. (ADMA) has a current PS of 7.25. The 5-year average PS is 4.26. The thresholds are as follows: Strongly Undervalued below -0.86, Undervalued between -0.86 and 1.70, Fairly Valued between 6.82 and 1.70, Overvalued between 6.82 and 9.38, and Strongly Overvalued above 9.38. The current Forward PS of 7.25 falls within the Overvalued range.

21.91

P/OCF

ADMA Biologics Inc. (ADMA) has a current P/OCF of 21.91. The 5-year average P/OCF is 8.86. The thresholds are as follows: Strongly Undervalued below -65.96, Undervalued between -65.96 and -28.55, Fairly Valued between 46.27 and -28.55, Overvalued between 46.27 and 83.68, and Strongly Overvalued above 83.68. The current Forward P/OCF of 21.91 falls within the Historic Trend Line -Fairly Valued range.

28.77

P/FCF

ADMA Biologics Inc. (ADMA) has a current P/FCF of 28.77. The 5-year average P/FCF is -1.66. The thresholds are as follows: Strongly Undervalued below -217.75, Undervalued between -217.75 and -109.71, Fairly Valued between 106.39 and -109.71, Overvalued between 106.39 and 214.43, and Strongly Overvalued above 214.43. The current Forward P/FCF of 28.77 falls within the Historic Trend Line -Fairly Valued range.

ADMA Biologics Inc (ADMA) has a current Price-to-Book (P/B) ratio of 10.24. Compared to its 3-year average P/B ratio of 10.27 , the current P/B ratio is approximately -0.30% higher. Relative to its 5-year average P/B ratio of 7.10, the current P/B ratio is about 44.34% higher. ADMA Biologics Inc (ADMA) has a Forward Free Cash Flow (FCF) yield of approximately 1.59%. Compared to its 3-year average FCF yield of -3.49%, the current FCF yield is approximately -145.63% lower. Relative to its 5-year average FCF yield of -22.17% , the current FCF yield is about -107.19% lower.

10.24

P/B

Median3y

10.27

Median5y

7.10

1.59

FCF Yield

Median3y

-3.49

Median5y

-22.17

Competitors Valuation Multiple

The average P/S ratio for ADMA's competitors is 32.44, providing a benchmark for relative valuation. ADMA Biologics Inc Corp (ADMA) exhibits a P/S ratio of 7.25, which is -77.64% above the industry average. Given its robust revenue growth of 13.80%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Kymera Therapeutics Inc

52.51

-55.26%

3.15B

Performance Decomposition

Market capitalization of ADMA increased by 2.83% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 107.19M to 121.98M.

The secondary factor is the P/E Change, contributed -4.75%to the performance.

Overall, the performance of ADMA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

13.80%

107.19M → 121.98M

Revenue Growth

-6.22%

29.91 → 28.05

Margin Expansion

-4.75%

21.24 → 20.24

P/E Change

2.83%